Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver Transplantation.

bioRxiv : the preprint server for biology·2026

Same author

When lipids silence immunity: Dendritic cell death in MASLD-associated HCC.

Journal of hepatology·2026

Same author

Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Same author

Allogeneic CRISPR-Engineered CAR-T Cells Drive Potent Antitumor Activity in Solid Tumors.

bioRxiv : the preprint server for biology·2026

Same author

Extended longitudinal validation of serum procalcitonin as a biomarker for fibrolamellar hepatocellular carcinoma.

Journal of hepatology·2026

Same author

Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy.

Cell reports. Medicine·2026

Search research articles

Related Experiment Video

Updated: Jul 27, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chimeric antigen receptor therapy for hepatocellular carcinoma.

Lorenz Kocheise¹, Mohamed-Reda Benmebarek¹, Mitchell Ho²

¹Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Seminars in Immunology

|March 12, 2026

Summary

Chimeric antigen receptor T cell (CAR T) therapy shows promise for hepatocellular carcinoma (HCC). The liver microenvironment presents unique challenges and opportunities for CAR T cell efficacy in treating this liver cancer.

Keywords:

CAR T cell Cellular therapies Chimeric antigen receptor GPC3 HCC Hepatocellular carcinoma

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Experiment Videos

Last Updated: Jul 27, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Area of Science:

Immunology
Oncology
Cellular Therapy

Background:

Adapting chimeric antigen receptor T cell (CAR T) therapy from blood cancers to solid tumors is challenging due to factors like poor T cell infiltration and antigen loss.
Hepatocellular carcinoma (HCC) has a unique liver microenvironment influenced by metabolism and the gut-liver axis, presenting specific hurdles and potential for cellular therapies.

Purpose of the Study:

To review the current status of CAR T cell therapy for hepatocellular carcinoma (HCC).
To explore the potential of HCC as a suitable target for tailored CAR T cell strategies, considering the liver's unique properties.

Main Methods:

Review of recent clinical and preclinical developments in CAR T cell therapy for HCC.
Analysis of the liver microenvironment's characteristics and their impact on cellular therapy efficacy.
Examination of HCC-specific antigens for targeted therapeutic approaches.

Main Results:

Solid tumors, including HCC, present significant challenges for CAR T cell therapy, limiting early clinical success.
Combinatorial strategies and next-generation CAR T cells are improving outcomes.
HCC's specific antigens and liver microenvironment offer unique opportunities for targeted CAR T cell therapies.

Conclusions:

Despite challenges, HCC may be particularly well-suited for advanced CAR T cell strategies due to its distinct immunological and anatomical features.
Tailored CAR T cell approaches hold significant promise for improving HCC treatment outcomes.
Further research into the interplay between CAR T cells and the liver microenvironment is crucial.